Gilead Sciences, Inc. (GILD) To Go Ex-Dividend on September 15th

Gilead Sciences, Inc. (NASDAQ:GILD) declared a quarterly dividend on Tuesday, July 28th. Stockholders of record on Tuesday, September 15th will be paid a dividend of 0.82 per share by the biopharmaceutical company on Tuesday, September 29th. This represents a c) dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date is Tuesday, September 15th.

Gilead Sciences has increased its dividend by an average of 0.0%per year over the last three years and has increased its dividend annually for the last 10 consecutive years. Gilead Sciences has a payout ratio of 38.5% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Gilead Sciences to earn $9.87 per share next year, which means the company should continue to be able to cover its $3.28 annual dividend with an expected future payout ratio of 33.2%.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $143.72 on Friday. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. The firm has a market cap of $178.21 billion, a P/E ratio of -53.83 and a beta of 0.33. The firm has a 50 day simple moving average of $138.48 and a 200 day simple moving average of $136.29. Gilead Sciences has a fifty-two week low of $108.46 and a fifty-two week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The firm had revenue of $7.80 billion during the quarter, compared to analysts’ expectations of $7.40 billion. Gilead Sciences’s revenue was up 10.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.01 EPS. Sell-side analysts predict that Gilead Sciences will post -0.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Truist Financial decreased their price target on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating on the stock in a report on Tuesday, July 7th. Wall Street Zen cut Gilead Sciences from a “buy” rating to a “hold” rating in a report on Saturday, September 5th. Daiwa Securities Group cut their target price on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 19th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $155.00 target price on shares of Gilead Sciences in a research note on Wednesday, August 5th. Finally, HSBC lifted their price target on shares of Gilead Sciences from $155.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $158.78.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company’s research focuses primarily on virology, oncology, inflammation and related areas, with products serving patients in the United States and international markets.

Gilead is best known for its HIV treatments, including Biktarvy, Genvoya, Descovy and other antiretroviral therapies. Its portfolio also includes medicines for viral hepatitis, such as Epclusa and Vemlidy, and Veklury (remdesivir), an antiviral treatment for COVID-19.